Biotech | April 03, 2022
USFDA approves Yescarta as first CAR T-cell therapy for Lymphoma
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Recommendation is based on pivotal data from the phase III POLARIX study
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Jaypirca is making waves in the fight against B-cell malignancies
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Subscribe To Our Newsletter & Stay Updated
